-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5

Benzinga·05/13/2026 17:14:46
Listen to the news
Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and lowers the price target from $6 to $5.